Financings in Brief: Boston Biomedica
This article was originally published in The Gray Sheet
Executive Summary
Boston Biomedica: Files registration statement with the Securities and Exchange Commission for an initial public offering with a proposed aggregate value of $22.1 mil. The manufacturer of quality control products for in vitro diagnostics plans to use $3.6 mil. of proceeds from the offering to repay debt; $1 mil. will fund an expansion of the firm's West Bridgewater, Massachusetts facilities. Remaining proceeds will be used for "general corporate purposes, including working capital, as well as for potential acquisitions and alliances," the registration statement says. Oscar Gruss & Son Incorporated and Kaufman Bros., L.P. are underwriting....